The purpose of our study is to determine the effect of prophylactic treatment with
brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL) or placebo therapy
(Refresh tears®, Allergan; Dublin, IRL) on long-term IOP measurements in patients receiving
serial intravitreal injection of 0.5 mg ranibizumab (0.05 mL) with six months follow-up.
Intraocular pressure measurements will be correlated with changes on ancillary testing
(Humphrey 24-2 visual field testing and optical coherence tomography (OCT) of the optic nerve
head (ONH). Our study would be the first large, prospective, randomized double-blind
placebo-controlled trial to examine the relationship between anti-vascular endothelial growth
factor (VEGF) therapy and sustained ocular hypertension.